AG Bonta files lawsuit against drug companies over insulin prices, joining other states
SACRAMENTO (CBS SF/AP) — California Attorney General Rob Bonta announced Thursday that his office is suing the companies that make and promote most of the nation's insulin, charging them of attempting to manipulate the market price of the drug.
In his statement, Bonta demanded they return millions of dollars to some diabetics who state officials say were overcharged for the medicine they must have to survive.
"People are losing their lives because they can't afford the drug," Bonta said.
The lawsuit, to be filed in Los Angeles County Superior Court by Bonta, is the latest in a parade of legal actions against these companies from states across the political spectrum — all who have accused the corporate giants of abusing their power to quash competition and boost their profits by keeping the price of insulin high.
Attorneys general in Kansas, Arkansas,Mississippi,Minnesota and Kentucky have all filed similar lawsuits in recent years.
"It is not a partisan issue," said Bonta, a Democrat who was elected to his first full term in November. Bonta said state attorneys general from both major political parties "all say the same thing: That the status quo is unacceptable and problematic and awful."
A 2021 study by the RAND Corporation comparing the insulin prices of nearly three dozen countries found prices in the United States were about 10 times higher than everywhere else. The average price of a vial of insulin in the United States was $98, while in nearby Canada it was $12.
Bonta sued three companies who make insulin — Eli Lilly, Novo Nordisk, and Sanofi — and three companies who manage prescription drug programs that provide insulin — CVS Caremark, Express Scripts and OptumRx.
Bonta said the manufacturers raise the price of insulin "in lockstep with each other." The prescription drug managers then negotiate with the manufacturers to get a percentage of that price in exchange for prominently promoting their high-price insulin over cheaper alternatives.
Insulin manufacturers and prescription drug managers often blame each other for these higher prices. Mike DeAngelis, executive director of corporate communications for CVS Health, said the manufacturers alone set the list price for their products.
"Nothing in our agreements prevents drug manufacturers from lowering the prices of their insulin products and we would welcome such action," he said. "Allegations that we play any role in determining the prices charged by manufacturers are false. We plan to vigorously defend against this complaint."
Representatives for Eli Lilly and Sanofi did not respond to a request for comment. A representative for Novo Nordisk declined to comment on the lawsuit. But the company provided some "background information" saying the net prices for it insulin products have fallen in each of the past five years "in large part to the significant rebates and discounts manufacturers pay to ensure access for patients."
Insulin is made by the pancreas and is used by the human body to convert the food we eat into energy. People who have diabetes don't produce enough insulin. People with Type 1 diabetes must take insulin every day to survive.
A team of Canadian scientists discovered insulin a century ago. They sold the patent to the University of Toronto for just $1 hoping to avoid a monopoly that could cause high prices. But eventually, the market came to be dominated by just three companies.
Kevin Wren, an activist associated with the California chapter of #Insulin4All, said he must take insulin every day to survive. Around 2009, Wren said he was working two jobs and did not have health insurance. He had to ration his insulin, taking less than the recommended dosage to make it last longer — a dangerous practice that he said ended up putting him in the hospital with ketoacidosis, a serious complication of diabetes.
Today, Wren says he has good health insurance and doesn't have to ration his supply of insulin. He said he skirts the law each month by providing people insulin from someone else's prescription "all so that they don't have to ration."
The big insulin manufacturing companies have assistance programs to help people purchase insulin. Novo Nordisk said in 2021, more than a million people used some form of the company's assistance when purchasing its insulin.
California's state government is considering making its own insulin and selling it at a much cheaper price. Last year, the state Legislature approved $100 million for the project, with $50 million set aside for developing three types of insulin and the rest going to a potential manufacturing facility.
State officials hope a California brand of generic insulin could disrupt the market and bring all insulin prices down. Bonta says he hopes his lawsuit does the same thing.
"California can drive markets," Bonta said, citing the state's size and economic power. "Change emanates and starts here."
